1,048
Views
30
CrossRef citations to date
0
Altmetric
Report

Lapatinib induces p27Kip1-dependent G₁ arrest through both transcriptional and post-translational mechanisms

, , , &
Pages 2665-2674 | Received 09 May 2013, Accepted 11 Jul 2013, Published online: 29 Jul 2013
 

Abstract

Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, has been shown to have potent antitumor effects against human breast cancer. Recent studies have shown that lapatinib upregulates p27Kip1 (here after referred to as p27) expression and induces G1 cell cycle arrest in various types of cancer cells. However, the regulation of p27 in lapatinib-induced cell cycle arrest is not well studied. Here we demonstrate that lapatinib-induced cell growth inhibition and G1 cell cycle arrest in HER2-overexpressing human breast cancer cells were dependent on p27. We also show that lapatinib-induced upregulation of p27 expression was mediated through both transcriptional and post-translational mechanisms. On the one hand, lapatinib treatment led to increased FOXO3a expression and enhanced p27 transcription. On the other hand, lapatinib treatment resulted in increased DYRK1B expression, which correlated with increased p27 phosphorylation at Ser10 and decreased p27 degradation. Interestingly, we found that ERβ1 but not ERβ2 expression also upregulated p27 and enhanced lapatinib-induced cell proliferation inhibition and G1 cell cycle arrest in HER2-overexpressing breast cancer cells. Taken together, our results suggest that lapatinib induces p27 expression via both transcriptional and post-translational upregulations, leading to cell cycle arrest and cell proliferation inhibition, and that its effect on breast cancer cells may be modified by ER expression status.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowlegements

This work was supported by The Cancer Prevention and Research Institute of Texas Grants HIRP100680 and RP110444, the Texas Emerging Technology Fund under Agreement 300-9-1958, the Robert A. Welch Foundation Grant E-0004, and the Swedish Cancer Fund (to JAG), and by grants from National Natural Science Foundation of China (no.81272252), Natural Science Foundation of Jiangsu Province (no. BK2011656) (to XG).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.